The DOI matches its Crossref record; 133 of the 135 references it cites were found in a registry or an index; 50 of the 139 sources its claims cite were checked for support.
Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy
Open accessAbstract
Gene therapy (GT) for ocular disorders has advanced the most among adeno-associated virus (AAV)-mediated therapies, with one product already approved in the market. The bank of retinal gene mutations carefully compiled over 30 years, the small retinal surface that does not require high clinical vector stocks, and the relatively immune-privileged environment of the eye explain such success. However, adverse effects due to AAV-delivery, though rare in the retina have led to the interruption of clinical trials. Risk mitigation, as the key to safe and efficient GT, has become the focus of ‘bedside-back-to-bench’ studies. Herein, we overview the inflammatory adverse events described in retinal GT trials and analyze which components of the retinal immunological environment might be the most involved in these immune responses, with a focus on the innate immune system composed of microglial surveillance. We consider the factors that can influence inflammation in the retina after GT such as viral sensors in the retinal tissue and CpG content in promoters or transgene sequences. Finally, we consider options to reduce the immunological risk, including dose, modified capsids or exclusion criteria for clinical trials. A better understanding and mitigation of immune risk factors inducing host immunity in AAV-mediated retinal GT is the key to achieving safe and efficient GT.
Overview
CoChat Summary
TL;DR
This review argues that immune responses—especially innate microglial and TLR9-mediated sensing of rAAV DNA/CpG sequences—are key risks for retinal gene therapy and can limit its safety and efficacy. It surveys trial adverse events and mitigation strategies including modified capsids, CpG-depleted/deimmunized vectors, lower doses, immunosuppression, and stricter patient exclusion criteria.
Key findings
- Retinal gene therapy has advanced with one approved product and about 30 active ocular clinical trials; innate and adaptive immune activation is frequent at doses above 1 × 10^11 vg, though humoral antibody responses to transgene products remain rare.
- Dose-dependent toxicity is reported: in the DME trial NCT04418427, high-dose intravitreal ADVM-022 caused increased ocular pressure in 5/12 and vision loss in 1/12; in X-linked retinoschisis, all patients injected with 1 × 10^11 vg displayed anterior chamber inflammation around 2 weeks and vitritis after a month, while only one patient at 1 × 10^10 vg and none at 1 × 10^9 vg developed similar adverse events.
- TLR9/MyD88 is described as the only DNA sensor experimentally proven to trigger rAAV-associated immunity; CpG content varies widely across vector elements (e.g., RF1 11.03% for ITR2, 11.62% for CBA, 10.73% for CAG, 13.83% for HSP, 5.94% for SpCas9, 5.32% for SaCas9). CpG-depleted/deimmunized vectors reduced innate and T cell responses, but in one intraocular study inflammation after 4 × 10^11 vg per eye was only delayed.
- Mitigation options include modified capsids, evading DNA sensing, decreasing dose, immunosuppression (glucocorticoids, rituximab, proteasome inhibitors, hydroxychloroquine), and stricter exclusion criteria such as NAbs above 1:1000, active ocular inflammation, or a history of severe vascular disease.
Methods
- Narrative review, not primary research; it synthesizes published retinal rAAV gene therapy trial immune responses and mechanistic literature on ocular immune privilege, microglia, DNA sensors, and vector/patient risk factors.
- Data include a non-exhaustive Table 1 of retinal GT trials with rAAV vectors and immune responses, and Table 2 calculating RF1 associated with CpG sequences in rAAV vector components (ITRs, promoters, transgenes, supplementary elements).
- Main analysis is qualitative: it compares trial routes and doses, discusses TLR9/MyD88 and other DNA sensors, and proposes risk-mitigation strategies; no systematic search or meta-analysis is described.
Limitations
- Stated: Table 1 is non-exhaustive; little information is available on effector T cell involvement in retinal degenerations; it remains open whether viral particles reach the nucleus in immune cells; there is no consensus on optimal immunomodulatory molecules and dosing; retrospective safety data are not always available; and more uniform adverse-event reporting is needed.
- Evident: as a narrative review, it does not provide new experimental data or quantify effect sizes; the CpG RF1 table is described as not showing direct TLR9 activation risk, which likely depends on CpG-DNA secondary structure.
- Evident: many cited trial results come from press releases or clinicaltrials.gov and may lack peer-reviewed detail; the review does not perform a systematic risk-of-bias assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Retinal immune system. (A) In normal immunological conditions, multiple mechanisms are dedicated to immune tolerance and immune privilege. (1) The blood-retina barrier, which is partly composed by tight junctions (depicted in yellow) between RPE cells, acts as a physical and immune bulwark. It blocks the entry of circulating immune cells inside the retina and prevents antigens from escaping the retina [14,15,16]. (2) The retinal microenvironment, composed of immunoinhibitory and trophic factors secreted by the RPE, Müller glial cells, or astrocytes, promotes cell survival and tolerogenic immune responses (impairment of activated T-cell and APC functions, promotion of T-reg induction, and mitigation of inflammatory processes) [8,17,18,19,20,21,22]. (3) Microglial cells, often described as immune wardens, constitute the bulk of the retinal immune cells. They are found in a resting state in the healthy retina [23,24]. (4) Microglial cells are assisted by the complement system, a few resident macrophages and other retinal cells that perform immune surveillance and can act as APCs: Müller glia, astrocytes, or RPE cells [25,26]. While the immune tolerance mechanism tries to counterbalance inflammation, danger signals in the retina may still result in mild activation of the innate immune system, in a process recently termed para-inflammation [27,28,29]. (B) During stronger challenges, disruption of the immune privilege may occur. Recruitment and activation of circulating or resident immune cells in the retina, potentially including T cells, usually result in a full-fledged immune response and inflammation, causing permanent tissue damage [30,31].](https://figures.cochat.ai/paper-figures/12a0c634314c456c8b4a832a7ec63175/risk-mitigation-of-immunogenicity-a-key-to-personalized-retinal-gene-therapy-figure-1.jpg)


Verification
Claims the paper makes
40 Valid · 10 Not valid · 57 Not checked · 48 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More recently, innate immune responses elicited by AAV that cause explicit inflammation have started to garner attention, putting into question the impeccable safety record of the recombinant vector [4][5][6].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 1. Introduction
What the sources say
- Partly supportedcites [4] Konkle, 2021, BAX 335 Hemophilia B Gene Therapy Clinical Trial Results—Potential Impact of CpG Sequences on Gene Expression, Blood sourceExperimental — accuracy not yet measured
Our copy does support the trend half of the sentence: the Discussion states that 'recent animal studies have unraveled additional innate immune interactions between AAV and host that may be at play and cannot be ignored,' that avoiding immune stimuli in the nucleotide sequence 'is increasingly recognized as an important general consideration,' and that transient IL-6 induction in participant 6 'may be further evidence of an innate immune response triggered by recombinant AAV in humans.' However, the paper never claims this calls the recombinant AAV safety record into question: it hedges its own causal attribution ('we suggest that innate immune stimulation... could have contributed to the loss of AAV vector–mediated gene expression'; 'future research will need to substantiate this hypothesis'), confines the observation to one trial's CpG-enriched BAX 335 cassette, and explicitly argues the vector production platform ran 'without similar incident' in other clinical studies. The citing sentence converts a hedged, single-trial hypothesis into an unhedged general indictment of vector safety, so that framing is not supported by this source. (LLM, conf=0.72)
- Not checked yetcites [5] Reichel, 2017, AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye, Mol. Ther. source
- Supportedcites [6] Shao, W., Earley, L.F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M.L., Ting, J., and Samulski, R.J. (2018). Double-Stranded RNA Innate Immune Response Activation from Long-Term Adeno-Associated Virus Vector Transduction. JCI Insight, 3. source
Our copy treats AAV-elicited innate immunity as an acknowledged, actively investigated concern: the Introduction (p. 1) states 'the innate immune response is immediately activated following AAV vector infection via TLR pathways,' and the Discussion (p. 11) recapitulates that PRR recognition 'upregulates costimulatory molecules and inflammatory cytokine production,' citing rapid inflammatory-cytokine induction after systemic AAV in mice (refs 30, 31) and TLR9/TLR2 activation in pDCs and nonparenchymal liver cells (refs 18, 19). The paper adds new evidence of late IFNβ/dsRNA-pathway activation in primary human hepatocytes (Results, p. 5; Figure 6) and states its results 'highlight the concern that dsRNA-mediated innate immune response is triggered in human hepatocytes from long-term AAV transduction' (Discussion, p. 12), invoking this response as 'an alternative mechanism for therapeutic failure' (p. 2). This matches the cited sentence's substance — inflammatory innate responses to AAV drawing attention and undermining confidence in the recombinant vector; the 'impeccable safety record' phrasing is the citing authors' rhetoric, but the concern it describes is stated in the source. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“While the immune tolerance mechanism tries to counterbalance inflammation, danger signals in the retina may still result in mild activation of the innate immune system, in a process recently termed para-inflammation [27][28][29].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 2. Immune Responses in Retinal Gene Therapy Trials
What the sources say
- Not checked yetcites [27] Medzhitov, 2008, Origin and Physiological Roles of Inflammation, Nature source
- Not checked yetcites [28] Xu, 2009, Para-Inflammation in the Aging Retina, Prog. Retin. Eye Res. source
- Supportedcites [29] Chen, 2015, Parainflammation, Chronic Inflammation and Age-Related Macular Degeneration, J. Leukoc. Biol. source
The Introduction states that para-inflammation is an adaptive response of the immune system to low levels of tissue stress, i.e. a low degree of 'danger' stimuli, and the 'Inflammation – an adaptive response to tissue stress' section attributes this term to Medzhitov, describing it as the innate immune response to tissue malfunction (DAMPs sensed by PRRs). The 'Para-inflammatory response by retinal immune system' section applies this to the retina, where resident microglia/macrophages/dendritic cells detect DAMPs and undergo low-level (mild) activation during aging, and the Abstract confirms the retinal innate immune system 'undergoes low levels of activation (para-inflammation)'. The 'Immune privilege property of the retina' section supports the framing that despite tolerance mechanisms, an immune response can still be mounted locally after noxious insults. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An active local or peripheral tolerance to prevent runaway immune responses can be induced in some cases through the conversion of T cell to regulatory T cells (Treg) or the apoptosis of infiltrated effector T cells by inhibitory molecules expressed on the retinal pigmented epithelium (RPE) or resident stromal cells [9][10][11].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 1. Introduction
What the sources say
- Not checked yetcites [9] Zamiri, 2005, Thrombospondin Plays a Vital Role in the Immune Privilege of the Eye, Investig. Ophthal. Vis. Sci. source
- Not checked yetcites [10] Griffith, 1996, CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance, Immunity source
- Partly supportedcites [11] Hori, 2006, B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts, J. Immunol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Topical application of CpG ODNs onto a scratched cornea was shown by Chinnery et al. to lead to inflammation in eye tissues including retina, after CpG leakage into the anterior segment [88].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 3.4. The TLR9/MyD88 Pathway Is Activated upon rAAV Transduction
What the sources say
- Supportedcites [88] Chinnery, 2012, TLR9 Ligand CpG-ODN Applied to the Injured Mouse Cornea Elicits Retinal Inflammation, Am. J. Pathol. source
The Results section 'CpG-ODN-Induced Keratitis Is Accompanied by Widespread Intraocular Inflammation' states that CpG-ODN applied to the debrided (scratched) corneal surface caused neutrophil/macrophage infiltration of the anterior uveal tract and anterior chamber plus vitreous haze and inflammatory infiltrates in the vitreous and retina (Figure 3C-I), and the Figure 3 legend dates this to 24 hours after topical application. The section 'CpG-ODN Applied to the Debrided Corneal Surface Quickly Reaches the Retina' and the Discussion support the mechanism in the claim — FITC-labelled CpG-ODN diffused through corneal stroma into the aqueous (anterior segment) and vitreous humour, with fluorescent signal throughout the posterior segment at 24 hours. The only unstated qualifier is the mouse model, which the citing sentence leaves generic. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammatory immune responses for ocular gene therapies become harder to predict in the clinical setting, as both physiological and barrier functions of immune privilege may already be compromised by aging or the ocular disorder physiopathological conditions such as inflammation or oxidative stress induction [21,66,67].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 3.1. Immune Privilege
What the sources say
- Could not verifycites [21] Wang, 2011, Adaptive Müller Cell Responses to Microglial Activation Mediate Neuroprotection and Coordinate Inflammation in the Retina, J. Neuroinflamm. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [66] DiSabato, 2016, Neuroinflammation: The Devil Is in the Details, J. Neurochem. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites [67] Verkhratsky, A., Noda, M., and Parpura, V. (2015). Microglia: Structure and Function. Brain Mapping, Elsevier. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
80 more claims · 29 with their cited sources checked
Create a free account to see all 155 claims and to verify the 89 references still open.
- It may state two separate claims as one. 53
- Probably not a substantial claim. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, subretinal injections have not been associated with severe inflammation following treatment with AAV8, AAV2, or AAV5, increasing its appeal as a route of administration.19,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have observed antidrug antibody responses and inflammation in the eyes due to immune cell infiltration following retinal gene therapy.21,23–27”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immunogenicity against the viral vector that limits gene therapy efficacy is a major concern.4,21,25,26,141 and is one of the biggest exclusion criteria in clinical trials.14,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the clinical setting, screening patients for presence of neutralizing antibodies for the gene therapy vector can improve outcomes.14,26,142”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Although there have been safety issues observed in gene therapy trials outside the eyes, few serious adverse events directly related to recombinant AAV gene therapies have been reported in ocular gene therapy trials.26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 6. Conclusions and Outlook
“| NCT01496040 | Nantes University Hospital | PI/II, NR, OL | 2 | hRPE65p | hRPE65 | 1.22 × 10 10 to 4.8 × 10 10 | SRI |”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > References
“43. Le Meur, G.; Lebranchu, P.; Billaud, F.; Adjali, O.; Schmitt, S.; Bézieau, S.; Péréon, Y.; Valabregue, R.; Ivan, C.; Darmon, C.; et al. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 5.2.2. Clinical Trial Criteria
“In the recent clinical trial for DME, all patients showing a strong decrease in intraocular pressure at high dose, had a history of severe vascular disease that potentially led to a pro-inflammatory ocular environment [7].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 1. Introduction
“Five patients suffered from a rapid increase in ocular pressure refractory to conventional drug treatments, leading to surgery for three and to loss of vision for one patient.”
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hammond, T. R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A. J., Segel, M., Nemesh, J., Saunders, A., et al. (2018) · doi:10.1101/406140 · Cited by 2,225
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Research works printed but not linked: 2
- (2021, October 30). Solid Biosciences Announces Clinical Hold on SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy. Available online: https://www.solidbio.com/about/media/press-releases/solid-biosciences-announces-clinical-hold-on-sgt-001-phase-i-ii-clinical-trial-for-duchenne-muscular-dystrophy.
- Michaelides, M., Besirli, C., Khan, K., Yang, Y., Wong, C., Sahel, J., Shah, M., Tee, J., Kumaran, N., and Georgiadis, A. (2020, January 13–15). AAV5-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 12-Month Results From a Phase 1/2 Clinical Trial. Proceedings of the AAO Virtual Meeting, Virtual.
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
“A better understanding and mitigation of immune risk factors that induce host immunity is the key to achieving better clinical results [114].”
BackgroundChauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05599-5 · Cited by 27
“Therefore, many investigators are working to develop engineered capsids that evade pre-existing neutralizing antibodies or induce milder immune responses, in the hope that this will allow for more sustained transgene expression and therapeutic benefit at lower doses [48–50].”
BackgroundMannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 18
“35 This dose dependence supports the need of new-generation rAAV vectors with an improved balance between ef fi cacy and safety.”
BackgroundSelf-citationMacLaren, R. E., Audo, I., Fischer, M. D., Huckfeldt, R. M., Lam, B. L., Pennesi, M. E., Sisk, R., Gow, J. A., Li, J., Zhu, K., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.017 · Cited by 15
“53,54 As expected in a safety study of this duration, BCVA was generally maintained in both eyes over 12 months after a single subretinal treatment in each eye.”
Metadata
- Authors
- Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T.
- Affiliations
- Inserm (FR)
- CHU de Nantes, INSERM UMR1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, F-44200 Nantes, France
- Corresponding author
- Adjali, Oumeya
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-26
- Volume
- 22
- Issue
- 23
- Pages
- 12818
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8658027
- OpenAlex
- W3215345544
- Semantic Scholar
- 96613e1fded62606e1613db34a1e7708c2db3238
- Cited by
- 19
- References
- 135
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 6 · 2023: 1 · 2022: 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- UpGrade Horizon2020 (825825)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- retinal gene therapy, adeno-associated virus vectors, immunogenicity, ocular inflammation, microglia, innate immunity, CpG motifs, dose optimization, exclusion criteria, personalized gene therapy
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Retinal Diseases, Transduction, Genetic, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy. https://app.cochat.ai/papers/10.3390/ijms222312818
- The paper
- Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021). Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222312818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.